For Highmark health insurance members, getting cancer treatment from UPMC doctors and hospitals will cost $200 million less over the next three years, the insurer began telling clients Wednesday.
The savings will come from lower rates reached through recent arbitration between Highmark and UPMC when compared to payments to UPMC for cancer care through the end of 2015, according to a letter sent by Highmark to insurance brokers.
Savings from cancer treatments combined with newly negotiated rates for hospital emergency room visits, other out-of-network services and fee schedule changes, Highmark officials say, could increase the total savings to members who use UPMC facilities to $550 million for the three-year period, which marks the end of a state-brokered consent decree between the two health care rivals.
Highmark’s letter to brokers comes on the heels of another arbitration decision in which the insurer ended up agreeing to pay UPMC up to $188 million for chemotherapy administered from 2014 through the end of this year.
Both decisions came in recent weeks as the health care titans try to unwind their ties.
In the cancer care decision that sets rates from January 2016 until mid-2019, Highmark touted the savings as benefiting members while giving the carrier a competitive advantage in the marketplace.
Read More
“Very important to note ... is that effective Jan. 1, 2016, we have achieved favorable rates for UPMC reimbursement when Highmark members use UPMC providers through the provisions outlined in the consent decrees for 2016 through 2019,” Highmark told brokers and members in a letter. “We estimate the savings to our customers to be nearly $200 million through the period as compared to rates being paid to UPMC in 2015.”
UPMC spokesman Paul Wood disputed Highmark’s assertions, saying the projected savings were “yet another example of Highmark’s bait and switch to sell insurance and retain customers.”
“The rate arbitration provides UPMC with increases in excess of inflation over the next three and a half years,” he said.
The two companies have been battling for years over contract issues involving reiumbursement, which UPMC claimed was too low.
The scuffle over the rates paid for chemotherapy began in April 2014 when Highmark became the first insurer in the country to challenge higher chemotherapy rates charged by a hospital system, an issue that has been percolating among insurers nationwide.
Medicare allows hospitals to bill at a higher rate for chemotherapy that is administered at a hospital clinic rather than a doctor’s office, even though the Medicare Payment Advisory Commission has recommended a single rate, regardless of where the care is provided.
In an editorial that appeared in The Hill, a Washington D.C.-based newspaper, Highmark chief medical officer Donald Fischer cited the example of a cancer patient whose cost of treatment and out-of-pocket expenses more than tripled, even though the office and chemotherapy used were the same. “It’s not right and it needs to change,” Dr. Fischer wrote in May.
Highmark is part of a Washington, D.C.-based group of insurers and others called the Alliance for Site-Neutral Medical Payment Reform that has been pressing for an end to reimbursement disparities based on where the care is provided.
Medicare’s provision for separate reimbursement rates depending on where care is rendered has prompted hospital systems to snap up physician practices and reclassify the offices as hospital outpatient facilities for billing purposes. That loophole is closing.
For doctors’ offices newly purchased by a health care system, the two-year federal budget and deficit limit law that was enacted Nov. 2 restricts Medicare reimbursement for care to the physician office rate.
Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699.






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.